Clinical Trial

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Name: A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies — clinical trial record (NCT06049667)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.

Trial Details

NCT Number	NCT06049667
Lead Sponsor	Nanjing Chia-tai Tianqing Pharmaceutical
Conditions	Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment	72 participants
Start Date	2023-08-07
Primary Completion	2026-08 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2023-09-22